Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone pain palliation with 85Sr therapy.

F Giammarile1, T Mognetti, C Blondet

  • 1Nuclear Medicine Department, Centre Léon Bérard, Lyon, France.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|April 21, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.

ESMO open·2021
Same author

Non-Oncological PET/CT imaging during SARS-CoV-2 pandemic.

Hellenic journal of nuclear medicine·2020
Same author

Correction to: Nuclear medicine services after COVID-19: gearing up back to normality.

European journal of nuclear medicine and molecular imaging·2020
Same author

Nuclear medicine services after COVID-19: gearing up back to normality.

European journal of nuclear medicine and molecular imaging·2020
Same author

COVID-19 pandemic: guidance for nuclear medicine departments.

European journal of nuclear medicine and molecular imaging·2020
Same author

Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence.

European journal of nuclear medicine and molecular imaging·2019

Strontium-85 (85Sr) effectively palliates metastatic bone pain, offering significant pain relief and improved quality of life for many patients. Early-stage disease and prostate cancer patients showed the best outcomes with this radionuclide therapy.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmacology

Background:

  • Metastatic bone pain significantly impacts patient quality of life.
  • Palliative care options for refractory bone pain are crucial.
  • Radionuclide therapy offers a systemic approach to pain management.

Purpose of the Study:

  • To evaluate the efficacy of Strontium-85 (85Sr) in palliating metastatic bone pain.
  • To assess the safety and tolerability of 85Sr therapy.
  • To identify patient subgroups that benefit most from 85Sr treatment.

Main Methods:

  • Retrospective study analyzing data from 108 patients treated between 1977 and 1992.
  • Intravenous administration of 85Sr chloride (mean activity 335 MBq).
  • Evaluation of pain, performance status, blood counts, and survival post-treatment.

Related Experiment Videos

Main Results:

  • 72.2% of patients experienced significant pain relief and improved quality of life at 12 weeks.
  • 49.1% of patients became completely pain-free, with benefits lasting a mean of 4.3 months.
  • Prostate cancer patients and those with early-stage metastatic disease showed the best response.

Conclusions:

  • Systemic radionuclide therapy with 85Sr is a feasible and effective palliative treatment for refractory bone pain.
  • 85Sr therapy achieved comparable response rates to other bone-seeking radionuclides like 89Sr.
  • Optimal patient selection, particularly early-stage disease and prostate cancer, enhances treatment outcomes.